CONMED (CNMD) Projected to Post Quarterly Earnings on Wednesday

CONMED (NYSE:CNMD - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Wednesday, July 30th. Analysts expect CONMED to post earnings of $1.13 per share and revenue of $338.42 million for the quarter. CONMED has set its FY 2025 guidance at 4.450-4.600 EPS.

CONMED (NYSE:CNMD - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.95 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.14. CONMED had a return on equity of 14.36% and a net margin of 9.02%. The business had revenue of $321.26 million during the quarter, compared to the consensus estimate of $313.38 million. During the same quarter in the previous year, the business earned $0.79 earnings per share. The business's revenue for the quarter was up 2.9% on a year-over-year basis. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Trading Up 2.8%

CNMD stock traded up $1.37 during trading on Friday, reaching $50.93. 322,750 shares of the stock traded hands, compared to its average volume of 466,648. The business's 50 day moving average price is $53.72 and its 200-day moving average price is $58.16. CONMED has a 52-week low of $46.00 and a 52-week high of $78.19. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.26 and a quick ratio of 1.00. The firm has a market capitalization of $1.58 billion, a PE ratio of 13.40, a P/E/G ratio of 1.27 and a beta of 1.20.

CONMED Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 3rd. Shareholders of record on Friday, June 13th were paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.57%. The ex-dividend date of this dividend was Friday, June 13th. CONMED's dividend payout ratio is presently 21.05%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CNMD. Wells Fargo & Company cut their price objective on CONMED from $70.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. Wall Street Zen cut CONMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Stifel Nicolaus cut CONMED from a "buy" rating to a "hold" rating and cut their price objective for the company from $75.00 to $55.00 in a research note on Monday, April 28th. JPMorgan Chase & Co. cut their price objective on CONMED from $70.00 to $58.00 and set a "neutral" rating on the stock in a research note on Thursday, May 1st. Finally, Needham & Company LLC cut CONMED from a "buy" rating to a "hold" rating and set a $61.00 price objective on the stock. in a research note on Thursday, June 12th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $62.20.

Insider Activity at CONMED

In other news, Director Charles Farkas sold 4,000 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $56.94, for a total transaction of $227,760.00. Following the completion of the transaction, the director directly owned 16,346 shares of the company's stock, valued at approximately $930,741.24. This represents a 19.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.10% of the company's stock.

Hedge Funds Weigh In On CONMED

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Intech Investment Management LLC lifted its position in shares of CONMED by 34.6% during the 1st quarter. Intech Investment Management LLC now owns 22,505 shares of the company's stock valued at $1,359,000 after acquiring an additional 5,780 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of CONMED by 5.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 82,686 shares of the company's stock valued at $4,993,000 after purchasing an additional 4,565 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of CONMED by 19.9% in the first quarter. AQR Capital Management LLC now owns 14,199 shares of the company's stock valued at $857,000 after purchasing an additional 2,357 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of CONMED by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company's stock valued at $1,108,000 after purchasing an additional 800 shares in the last quarter.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.